background
respoc
studi
demonstr
syndrom
molecular
pointofcar
test
poct
respiratori
virus
associ
earli
discontinu
unnecessari
antibiot
compar
routin
clinic
care
subgroup
analysi
suggest
chang
occur
predominantli
patient
exacerb
airway
diseas
use
molecular
poct
respiratori
virus
becom
widespread
lack
evid
inform
choic
multiplex
syndrom
panel
versu
poct
influenza
materialsmethod
evalu
patient
respoc
studi
exacerb
asthma
copd
treat
antibiot
durat
antibiot
proport
earli
discontinu
compar
patient
test
posit
neg
virus
poct
control
patient
test
posit
virus
poct
compar
accord
viru
type
result
patient
exacerb
airway
diseas
receiv
antibiot
poct
group
control
group
poct
group
patient
test
posit
virus
test
posit
virus
earli
discontinu
antibiot
versu
test
neg
control
p
posit
virus
poct
posit
influenza
rhinoviru
virus
proport
earli
discontinu
antibiot
differ
viru
type
p
conclus
data
suggest
syndrom
molecular
poct
respiratori
virus
favour
poct
influenza
alon
adult
exacerb
airway
diseas
antimicrobi
resist
amr
arguabl
one
greatest
threat
global
human
health
driven
overus
antibiot
antibiot
prescrib
vast
major
patient
hospitalis
acut
respiratori
ill
ari
includ
clinic
group
virus
strongli
implic
aetiolog
asthma
exacerb
associ
respiratori
viru
infect
especi
rhinoviru
randomis
control
trial
fail
demonstr
benefit
antibiot
treatment
addit
larg
retrospect
observ
studi
nearli
patient
hospitalis
exacerb
suggest
antibiot
use
improv
outcom
associ
higher
cost
profession
societi
strongli
discourag
use
antibiot
asthma
exacerb
nation
guidelin
despit
antibiot
use
adult
hospitalis
exacerb
asthma
remain
common
patient
hospitalis
exacerb
copd
also
routin
treat
antibiot
despit
virus
frequent
implic
aetiolog
lack
high
qualiti
evid
benefit
patient
nonlif
threaten
exacerb
sever
randomis
trial
biomarkerdirect
therapi
show
antibiot
use
safe
reduc
noncrit
ill
hospitalis
patient
exacerb
copd
low
level
crp
procalcitonin
support
concept
antibiot
current
overus
popul
diagnost
uncertainti
regard
aetiolog
exacerb
airway
diseas
contribut
ongo
overus
antibiot
group
uk
depart
health
commiss
report
antimicrobi
resist
specif
note
import
rapid
diagnost
test
help
combat
amr
effect
antibiot
stewardship
recommend
prescrib
antibiot
inform
diagnost
test
one
exist
rapid
molecular
test
respiratori
virus
could
potenti
fulfil
need
patient
hospitalis
exacerb
airway
diseas
respoc
studi
larg
pragmat
randomis
control
trial
evalu
clinic
impact
syndrom
ie
comprehens
multiplex
pcr
pointofcar
test
poct
respiratori
virus
adult
present
hospit
acut
respiratori
ill
demonstr
syndrom
poct
respiratori
virus
use
fimarray
respiratori
panel
associ
sever
clinic
benefit
compar
routin
clinic
care
laboratori
test
includ
earlier
discontinu
antibiot
without
increas
advers
event
subgroup
analysi
trial
suggest
antibiot
chang
occur
predominantli
patient
exacerb
airway
diseas
test
posit
virus
littl
differ
seen
antibiot
use
clinic
group
patient
commun
acquir
pneumonia
patient
test
neg
virus
sever
observ
studi
support
find
respoc
demonstr
reduct
unnecessari
antibiot
rapid
molecular
test
respiratori
virus
varieti
clinic
set
addit
post
hoc
analysi
trial
suggest
rapid
turnaround
time
result
seen
poct
compar
laboratori
test
critic
modifi
antibiot
use
hospitalis
patient
sever
rapid
molecular
test
platform
respiratori
virus
avail
potenti
deploy
poct
clinic
area
use
hospit
becom
widespread
howev
lack
evid
inform
clinician
hospit
choic
multiplex
syndrom
panel
filmarray
rp
test
comprehens
rang
respiratori
virus
platform
test
influenza
influenza
rsv
rapid
accur
influenza
detect
clearli
prioriti
hospit
period
intens
influenza
transmiss
correctli
rapidli
administ
influenza
antivir
effici
utilis
infect
control
facil
addit
multiplex
syndrom
panel
expens
uniplex
test
influenza
current
clear
addit
clinic
valu
gain
test
viru
type
hospitalis
patient
analysi
examin
detail
chang
antibiot
use
associ
syndrom
molecular
poct
among
patient
exacerb
airway
diseas
determin
import
chang
antibiot
manag
occur
due
detect
noninfluenza
virus
studi
design
inclus
exclus
criteria
outcom
measur
baselin
popul
characterist
respoc
studi
previous
describ
origin
report
trial
brief
adult
present
emerg
depart
acut
medic
unit
ari
recruit
present
randomis
receiv
poct
respiratori
virus
use
filmarray
respiratori
panel
routin
clinic
care
studi
approv
north
west
preston
region
ethic
committe
protocol
public
avail
analysi
evalu
patient
exacerb
asthma
copd
treat
antibiot
durat
antibiot
proport
treat
singl
dose
short
cours
defin
less
h
compar
patient
test
posit
virus
poct
test
neg
poct
control
patient
patient
test
posit
virus
poct
compar
accord
viru
type
detect
kaplanmei
curv
gener
durat
antibiot
use
earli
discontinu
antibiot
defin
receipt
less
h
antibiot
stop
includ
receiv
singl
dose
rhinoenteroviru
codetect
influenza
rsv
influenza
rsv
consid
domin
patient
classifi
accordingli
statist
analys
done
use
prism
version
graphpad
softwar
la
jolla
ca
usa
stata
version
statacorp
colleg
station
tx
usa
compar
durat
antibiot
use
group
use
median
differ
kruskalw
test
differ
proport
use
chi
squar
test
fisher
exact
test
appropri
kaplanmai
curv
durat
antibiot
gener
compar
use
log
rank
test
patient
exacerb
airway
diseas
poct
group
asthma
copd
receiv
antibiot
patient
exacerb
airway
diseas
control
group
asthma
copd
receiv
antibiot
differ
antibiot
use
poct
control
group
ci
p
poct
group
patient
test
posit
respiratori
virus
receiv
antibiot
patient
test
neg
virus
receiv
antibiot
differ
antibiot
use
poct
posit
neg
patient
ci
p
baselin
characterist
patient
test
posit
neg
poct
control
patient
well
match
includ
physiolog
observ
laboratori
result
patient
control
group
test
respiratori
virus
use
laboratori
pcr
median
turnaround
time
result
h
compar
h
test
poct
p
tabl
test
posit
virus
poct
receiv
antibiot
earli
discontinu
antibiot
versu
test
neg
control
patient
p
median
durat
antibiot
day
test
posit
poct
versu
day
test
neg
poct
day
control
group
p
median
durat
iv
antibiot
h
ie
singl
dose
test
posit
poct
versu
test
neg
h
control
group
p
antibiot
use
poct
result
control
patient
shown
tabl
kaplanmei
curv
analysi
durat
antibiot
shown
fig
although
curv
three
group
poct
posit
poct
neg
control
becom
similar
approxim
day
start
antibiot
curv
show
sharp
reduct
antibiot
use
earli
test
posit
virus
poct
p
test
virus
poct
posit
influenza
b
posit
rhinoenteroviru
posit
virus
combin
rsv
parainfluenza
human
metapneumoviru
human
coronaviru
fig
codetect
rsv
rhinoenteroviru
influenza
human
coronaviru
rsv
hmpv
human
coronaviru
patient
receiv
poc
test
fig
among
posit
virus
receiv
antibiot
proport
earli
discontinu
antibiot
differ
viru
type
influenza
rhinoviru
virus
combin
p
antibiot
use
viru
type
shown
tabl
higher
proport
patient
influenza
receiv
iv
antibiot
compar
rhinoenteroviru
viru
type
vs
p
median
durat
iv
antibiot
antibiot
differ
viru
type
although
small
number
individu
viru
type
make
definit
statement
difficult
surviv
analysi
show
differ
earli
antibiot
discontinu
viru
type
p
fig
studi
show
syndrom
molecular
poct
respiratori
virus
adult
present
hospit
exacerb
airway
diseas
lead
reduct
antibiot
use
due
earli
discontinu
test
posit
virus
virus
detect
patient
noninfluenza
virus
rhinoenteroviru
commonli
detect
singl
viru
type
differ
rate
antibiot
discontinu
differ
viru
type
note
respoc
studi
poct
lead
reduct
proport
treat
antibiot
compar
routin
clinic
care
howev
unsurpris
patient
start
antibiot
earli
patient
journey
admit
hospit
often
result
poct
made
avail
reason
antibiot
stop
earli
patient
exacerb
airway
diseas
test
posit
virus
unknown
like
due
clinician
feel
detect
viru
adequ
explain
acut
ill
give
confid
bacteri
infect
unlik
longer
need
cover
antibiot
combin
data
crp
level
radiolog
result
expect
rhinoenteroviru
frequent
detect
viru
group
type
viru
detect
seem
influenc
decis
stop
antibiot
earli
although
number
group
small
definit
exclud
differ
suggest
patient
exacerb
airway
diseas
respiratori
viru
test
perform
pointofcar
use
comprehens
syndrom
multiplex
panel
rather
molecular
poct
influenza
alon
would
detect
major
virus
associ
earli
antibiot
discontinu
could
argu
mani
patient
studi
treat
antibiot
treat
case
clinic
ground
alon
given
antibiot
use
patient
asthma
exacerb
alreadi
strongli
discourag
nation
societi
guidelin
howev
despit
guidelin
inappropri
antibiot
use
hospitalis
patient
asthma
remain
common
diagnost
uncertainti
regard
possibl
bacteri
infect
especi
earli
part
hospit
admiss
diagnost
inform
avail
like
key
driver
practic
earli
provis
accur
result
regard
exacerb
aetiolog
seem
assist
ration
antibiot
decis
make
potenti
altern
complementari
strategi
biomarkerdirect
therapi
addit
reason
beyond
antibiot
stewardship
benefit
choos
test
use
comprehens
syndrom
poct
rang
respiratori
virus
rather
poct
influenza
alon
although
molecular
poct
platform
influenza
diagnost
accuraci
compar
laboratori
pcr
other
demonstr
inferior
sensit
nonindustri
sponsor
real
world
studi
potenti
reduc
use
hospit
set
miss
diagnos
seriou
consequ
includ
nosocomi
transmiss
influenza
although
influenza
may
repres
prioriti
hospit
infect
control
team
peak
influenza
season
detect
respiratori
virus
also
import
infect
control
purpos
virus
also
pose
seriou
risk
nosocomi
transmiss
outbreak
especi
danger
immunocompromis
patient
certain
high
risk
area
haematolog
ward
renal
unit
hospit
twostep
test
process
adopt
patient
neg
influenza
poct
test
use
multiplex
laboratori
pcr
increas
cost
prolong
time
result
avail
compar
comprehens
syndrom
poct
regulatori
consider
also
import
rapid
diagnost
platform
may
abl
use
poct
certain
countri
due
regulatori
requir
exampl
current
filmarray
system
fulli
clia
waiv
us
signific
consider
obvious
higher
cost
associ
syndrom
panel
versu
molecular
poct
influenza
clearli
need
health
econom
studi
provid
evid
cost
effect
approach
consid
increment
benefit
syndrom
test
lower
rate
readmiss
seen
test
posit
virus
versu
test
neg
control
patient
reason
clear
may
nonvir
exacerb
higher
rate
subsequ
exacerb
even
clariti
around
aetiolog
exacerb
may
reduc
readmiss
although
respoc
studi
publish
randomis
control
trial
syndrom
respiratori
viru
test
pointofcar
nonrandomis
pre
post
intervent
studi
suggest
similar
benefit
rapid
syndrom
respiratori
viru
test
term
reduc
unnecessari
antibiot
use
paediatr
adult
patient
present
hospit
strength
studi
includ
randomis
natur
parent
studi
larg
overal
cohort
patient
studi
pragmat
natur
broad
generalis
uk
intern
centr
limit
includ
singlecentr
trial
rel
small
number
patient
asthma
copd
respiratori
viru
detect
although
like
generalis
centr
rule
chang
seen
depend
process
care
uk
hospit
also
current
uncertain
molecular
poct
respiratori
virus
best
implement
within
nh
health
system
potenti
model
includ
train
clinic
staff
perform
test
develop
dedic
pointofcar
test
laboratori
staf
technician
locat
within
close
acut
area
conclus
syndrom
molecular
poct
respiratori
virus
adult
exacerb
airway
diseas
associ
earli
discontinu
unnecessari
antibiot
test
posit
virus
virus
detect
noninfluenza
virus
differ
antibiot
discontinu
differ
viru
type
result
suggest
syndrom
molecular
poct
respiratori
virus
favour
poct
influenza
alon
adult
exacerb
airway
diseas
univers
southampton
manufactur
molecular
test
platform
biofir
diagnost
llc
salt
lake
citi
utah
us
role
studi
concept
design
data
analysi
manuscript
prepar
correspond
author
full
access
data
final
respons
submit
public
report
independ
research
support
nation
institut
health
research
nihr
post
doctor
fellowship
dr
tristan
clark
pdf
view
express
public
author
necessarili
nh
nation
institut
health
research
depart
health
